Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan - Marketscreener.com
| PHARM Stock | EUR 0.83 0.02 2.35% |
About 61% of Pharming Group's investor base is looking to short. The analysis of current outlook of investing in Pharming Group NV suggests that many traders are alarmed regarding Pharming Group's prospects. The current market sentiment, together with Pharming Group's historical and current headlines, can help investors time the market. In addition, many technical investors use Pharming Group NV stock news signals to limit their universe of possible portfolio assets.
Pharming |
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan Marketscreener.com
Read at news.google.com
 |
Pharming Group Fundamental Analysis
We analyze Pharming Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Pharming Group is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Pharming Group NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharming Group stock to make a market-neutral strategy. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics with similar companies.
Peers
Pharming Group Related Equities
| BAMNB | Koninklijke BAM | 5.01 | ||||
| GLPG | Galapagos | 0.78 | ||||
| PNL | PostNL NV | 1.94 | ||||
| FUR | Fugro NV | 2.24 | ||||
| AMG | AMG Advanced | 3.42 |
Complementary Tools for Pharming Stock analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |